EST
SUPN icon

EA Series Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

EA Series Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.57M Buy
+52,192
New +$1.83M 0.06% 489

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EA Series Trust's SUPN Position: Q2 2023 in Review

EA Series Trust opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2023: 52,192 shares worth $1.57M. The stake represents 0.06% of the portfolio and ranks #489 among its holdings.

249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • EA Series Trust held 52,192 shares of Supernus Pharmaceuticals worth $1.57M as of Q2 2023.
  • Supernus Pharmaceuticals was a new EA Series Trust position in Q2 2023.
  • Supernus Pharmaceuticals made up 0.06% of EA Series Trust's portfolio in Q2 2023, its #489 holding.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.